Klacid is a Prescription medicine

Main Indication

Changes to the Klacid Product Information (PI):

Please note the following changes of clinical significance to the Klacid Product Information; date of most recent amendment 17 June 2014.

Note that other amendments, not listed below, were also made. Please refer to the full Product Information available via the button to the right.

    •    Addition: “Concomitant administration with ticagrelor or ranolazine is contraindicated.”
    •    Expansion of the contraindication to use with colchicine to include all patients: “Clarithromycin (and other strong CYP3A4 inhibitors) should not be used concomitantly with colchicine (see PRECAUTIONS and INTERACTIONS WITH OTHER MEDICINES).
  •          PRECAUTIONS:
    •    Addition: “Caution is advised regarding concomitant administration of clarithromycin with other ototoxic drugs, especially with aminoglycosides. Monitoring of vestibular and auditory function should be carried out during and after treatment.


Therapeutic Area


Sponsored By: Abbott

Medical Queries: 1800 225 311

Product Information for Klacid
Consumer Medicine Information for Klacid